Apixaban
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Deep-Vein Thrombosis
Conditions
Deep-Vein Thrombosis
Trial Timeline
Nov 1, 2005 → Feb 1, 2007
NCT ID
NCT00252005About Apixaban
Apixaban is a phase 2 stage product being developed by Bristol Myers Squibb for Deep-Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00252005. Target conditions include Deep-Vein Thrombosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05187286 | Pre-clinical | Active |
| NCT03594045 | Phase 2 | Terminated |
| NCT02958969 | Approved | Completed |
| NCT03456648 | Phase 2 | Completed |
| NCT02714855 | Pre-clinical | Completed |
| NCT02345343 | Pre-clinical | Completed |
| NCT01885585 | Pre-clinical | Completed |
| NCT02153424 | Pre-clinical | Withdrawn |
| NCT02101112 | Phase 1 | Completed |
| NCT01884350 | Approved | Completed |
| NCT01885598 | Pre-clinical | Completed |
| NCT00252005 | Phase 2 | Completed |
Competing Products
1 competing product in Deep-Vein Thrombosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalteparin sodium injection + Warfarin | Pfizer | Approved | 84 |